Show Summary Details
Page of

Heart failure in women 

Heart failure in women
Chapter:
Heart failure in women
Author(s):

Vera Regitz-Zagrosek

DOI:
10.1093/med/9780198784906.003.0680_update_001

Update:

Some novel concepts of HF and its therapy

Supra-normal EF is emerging as a new HF entity, mainly in women

Women apparently need lower doses of ACEI and beta-blockers than men and respond better to ARB/neprilysin inhibitors

Sex differences in effects of novel drugs and in adverse effects are rarely reported, even though the data are generally available in large RCTs.

Updated on 1 October 2020. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 April 2021

Heart failure in women frequently occurs at an older age than in men with less ischaemic aetiology and is more frequently characterized by preserved ejection function. Gene expression profiles in heart failure are different in both sexes. Sex-specific activation of ion channels may lead to differences in arrhythmia propensity, and QT prolongation. Women develop smaller and stiffer hearts under stress, whereas in men, eccentric hypertrophy seems to dominate. Imaging is crucial for the diagnosis, and cardiac dimensions should be normalized to body surface. Differences in medical therapy exist, and women are less frequently referred for resynchronization therapy and heart transplantation than men.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.